Please visit answersincme.com/GXD860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in gynecologic oncology discusses the evolving role of antibody-drug conjugates (ADCs) in HER2-expressing solid tumors. Upon completion of this activity, participants should be better able to: Recognize the role of human epidermal growth factor receptor 2 (HER2) in the pathogenesis of various solid tumors; Describe strategies to optimize HER2 biomarker testing in patients with various solid tumors; Review the evidence for HER2-directed antibody-drug conjugates (ADCs) that have demonstrated benefits in multiple types of HER2-expressing solid tumors; and Outline practical approaches to enhance outcomes for patients receiving HER2-directed ADCs for various solid tumors.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related